UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/721,022	11/25/2003	Mary Ann Lukas-Laskey	04012.0384	3995	
22852 7590 02/15/2008 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			EXAMINER		
			SPIVACK, PHYLLIS G		
			ART UNIT	PAPER NUMBER	
			1614		
			MAIL DATE	DELIVERY MODE	
			02/15/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/721,022	LUKAS-LASKEY ET AL.		
Examiner	Art Unit		
Phyllis G. Spivack	1614		

	Phyllis G. Spivack	1614					
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress				
THE REPLY FILED 31 December 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1. The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:	the same day as filing a Notice of ving replies: (1) an amendment, aftice of Appeal (with appeal fee) in	Appeal. To avoid aba fidavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)				
a) The period for reply expires 3 months from the mailing date	of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to Examiner Note: If box 1 is checked, check either box (a) or (TWO MONTHS OF THE FINAL REJECTION. See MPEP 70	ater than SIX MONTHS from the mailin b). ONLY CHECK BOX (b) WHEN THI	g date of the final rejecti	on.				
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	ension and the corresponding amount shortened statutory period for reply orig than three months after the mailing da	of the fee. The appropr inally set in the final Offi	iate extension fee ce action; or (2) as				
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter a Notice of Appeal has been filed, any reply must be filed 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	ns of the date of e appeal. Since				
AMENDMENTS							
3. ☐ The proposed amendment(s) filed after a final rejection, l (a) ☐ They raise new issues that would require further col (b) ☐ They raise the issue of new matter (see NOTE belowed)	nsideration and/or search (see NO		ecause				
(c) They are not deemed to place the application in bet	ter form for appeal by materially re	ducing or simplifying	the issues for				
appeal; and/or (d) ☐ They present additional claims without canceling a €	corresponding number of finally rei	ected claims					
, ,	corresponding framber of linary rej	ected claims.					
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.12	21 See attached Nation of Non Co	maliant Amandment	(DTOL 324)				
5. Applicant's reply has overcome the following rejection(s).		impliant Amendment	,F10L-324).				
 Applicant's reply has overcome the following rejection(s). Newly proposed or amended claim(s) would be all non-allowable claim(s). 		timely filed amendme	ent canceling the				
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to:		ll be entered and an e	explanation of				
Claim(s) rejected: <u>1-30</u> .							
Claim(s) withdrawn from consideration:							
AFFIDAVIT OR OTHER EVIDENCE							
B. The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).							
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome all rejections under appe	al and/or appellant fai	ils to provide a				
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.							
REQUEST FOR RECONSIDERATION/OTHER							
11. The request for reconsideration has been considered bu	t does NOT place the application in	n condition for allowa	nce because:				
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).							
13. ☑ Other: <u>See Continuation Sheet</u> .		PHYLLIS S	pwack				
February 11, 2008	Phyllis G. Spivack Primary Examiner Art Unit: 1614	PHYLLI8 S PRIMARY EX	PIVACK (AMINIETI				

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06) Continuation of 13. Other: A Fourth Supplemental Reissue Declaration filed January 17, 2008 under 37 CFR 1.172 and 1.175 is acknowledged.

In the last Office Action, which was a Final Rejection, claim 9 remained rejected under 35 U.S.C 102 (a) as being anticipated by Metra et al., Journal of the American College of Cardiology. In setting forth the reasons why the rejection was maintained, the Examiner stated the present claims fail to recite a "rate." See page 6. This statement was not intended to be a suggestion or a directive, but rather merely an observation. The term mortality "rate" is not deemed to be new matter. However, mortality "rate," as stated in claim 9, cannot be reduced to a single subject. It would have reasonably been reduced in a group of subjects. Therefore, the presentation of the term constitutes new matter. Further, since the term "rate" can only apply to a group of patients, the claim is confusing.